Development and Evaluation of Nyctanthes arbor-tristis (Harsingar)– Based Emulgel for the Treatment of Gouty Inflammation
International Journal of Drug Delivery Technology · 19.05.2026 · 16 (30s)
DOI: 10.25258/ijddt.16.30s.48 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 19.05.2026. Verfasst von Shadab Mobeen und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Gout is a long-standing inflammatory condition marked by repeated episodes of acute joint pain and swelling, primarily caused by the deposition of monosodium urate crystals. These crystals trigger innate immune responses and promote the generation of reactive oxygen species, leading to oxidative stress and sustained inflammation within the joints. Standard treatment options, including non-steroidal anti-inflammatory drugs, colchicine, and urate-lowering therapies, are commonly prescribed; however, their prolonged use is often associated with adverse systemic effects, reduced patient compliance, and safety years, there has been increasing interest in the use of plant-derived therapeutics in combination with novel topical delivery systems as a safer and more targeted approach for managing gout-related inflammation. Nyctanthes arbor-tristis (commonly known as Harsingar) is a well-recognized medicinal plant in traditional systems of medicine, known for its anti-inflammatory, antioxidant, analgesic, and immunoregulatory activities. These therapeutic properties are largely attributed to its diverse phytochemical profile, including iridoid glycosides, flavonoids, and various phenolic constituents. This review provides a comprehensive overview of gout pathogenesis and establishes a connection between disease mechanisms and the pharmacological actions of Harsingar. Special emphasis is placed on its potential to regulate inflammatory cytokines, reduce oxidative stress, and influence immune cell responses involved in the progression of gout. Additionally, the application of emulgel-based topical formulations is explored as an effective strategy to enhance drug stability, improve skin penetration, and increase localized therapeutic availability of Harsingar-derived bioactive compounds. By combining traditional knowledge with modern formulation approaches and mechanistic understanding, this review proposes Harsingar-loaded emulgels as an innovative and multi-targeted therapeutic option for gout management. It also outlines existing limitations in current research and highlights the need for further studies to support clinical applicability and large-scale use.
Zitieren
APA
Mobeen, S., Singh, B., Shukla, K. S., Singh, S., Sinha, S., Yadav, S. P., Ankur, A., Siddique, J., & Srivastava, A. K. (2026). Development and Evaluation of Nyctanthes arbor-tristis (Harsingar)– Based Emulgel for the Treatment of Gouty Inflammation. International Journal of Drug Delivery Technology, 16(30s). https://doi.org/10.25258/ijddt.16.30s.48
Vancouver
Mobeen S, Singh B, Shukla KS, Singh S, Sinha S, Yadav SP, et al. Development and Evaluation of Nyctanthes arbor-tristis (Harsingar)– Based Emulgel for the Treatment of Gouty Inflammation. International Journal of Drug Delivery Technology. 2026;16(30s). doi:10.25258/ijddt.16.30s.48
BibTeX
@article{Mobeen2026,
author = {Mobeen, Shadab and Singh, Bandana and Shukla, Karuna Shanker and Singh, Shalini and Sinha, Shweta and Yadav, Surya Prakash and Ankur, Ankur and Siddique, Junaid and Srivastava, Ayush Kumar},
title = {Development and Evaluation of Nyctanthes arbor-tristis (Harsingar)– Based Emulgel for the Treatment of Gouty Inflammation},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {30s},
doi = {10.25258/ijddt.16.30s.48}
}
EUVIMED